Oncology News

Researchers at the University of Louisville received a federal grant of more than $11.5 million to study liver cancer, non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, alcoholic liver disease and environmental toxicology and liver disease, and with future research focusing on infectious and viral liver disease and drug-induced liver injury, according to a press release.

United States military veterans had an increased frequency of hepatocellular carcinoma at autopsy compared with the general population, according to recent findings published in Clinical Gastroenterology and Hepatology.

Between 2000 and 2014, the individual risk for HBV-related hepatocellular carcinoma in New South Wales, Australia declined, according to recent findings published in the Journal of Hepatology. However, population level HBV-related HCC stayed the same.

The size of hepatocellular adenoma tumors shrinks after menopause in women aged older than 50 years, according to recent findings published in Clinical Gastroenterology and Hepatology.

BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.

The WHO’s International Agency for Research on Cancer working group identified an additional eight types of cancer associated with excess body fatness, including multiple myeloma; meningioma; and cancers of the gastric cardia, liver, gallbladder, pancreas, ovary and thyroid.

Patients with hepatitis C virus, but without hepatocellular carcinoma treated with direct-acting antiviral agents saw lower MELD scores and improved liver function, enabling some of them to be removed from the liver transplant list.

The Organ Procurement and Transplantation Network and the United Network for Organ Sharing Liver and Intestinal Organ Transplantation committee proposed an eight-district redistribution for liver transplants. The committee members predict their model will cut in half the current variance in median MELD at transplant.

Having non-hepatitis C virus cirrhosis and diabetes puts patients at a higher risk for developing hepatocellular carcinoma, according to research recently published in The American Journal of Gastroenterology.

A phase 2 trial designed to evaluate ENMD-2076 for the treatment of fibrolamellar carcinoma met its stage 1 endpoint of objective response for nonfutility based on prespecified interim analysis criteria, according to the agent’s manufacturer.